Vascular Endothelial Growth Factor in Tear Samples of Patientswith Systemic Sclerosis

Rentka, Anikó; Hársfalvi, Jolán; Berta, András; Köröskényi, Krisztina; Szekanecz, Zoltán; Szűcs, Gabriella; Szodoray, Péter; Kemény-Beke, Ádám

doi:10.1155/2015/573681

Cited by 22 publications

(19 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the eye, SyS commonly presents as dry eye, due to fibrosis of the lacrimal gland, as well as conjunctival telangiectasia and filamentous keratitis [ 158 ]. Despite these ocular manifestations, only two studies have investigated tear fluid proteomics in SyS to date [ 159 , 160 ]. In the first instance, Rentka et al [ 159 ] assessed tear fluid levels of the pro-angiogenic protein, VEGF, in 43 SyS patients and 27 healthy controls.…”

Section: Tear Fluid Analysis In Systemic Diseasesmentioning

confidence: 99%

Tear fluid biomarkers in ocular and systemic disease: potential use for predictive, preventive and personalised medicine

2016

View full text Add to dashboard Cite

In the field of predictive, preventive and personalised medicine, researchers are keen to identify novel and reliable ways to predict and diagnose disease, as well as to monitor patient response to therapeutic agents. In the last decade alone, the sensitivity of profiling technologies has undergone huge improvements in detection sensitivity, thus allowing quantification of minute samples, for example body fluids that were previously difficult to assay. As a consequence, there has been a huge increase in tear fluid investigation, predominantly in the field of ocular surface disease. As tears are a more accessible and less complex body fluid (than serum or plasma) and sampling is much less invasive, research is starting to focus on how disease processes affect the proteomic, lipidomic and metabolomic composition of the tear film. By determining compositional changes to tear profiles, crucial pathways in disease progression may be identified, allowing for more predictive and personalised therapy of the individual.This article will provide an overview of the various putative tear fluid biomarkers that have been identified to date, ranging from ocular surface disease and retinopathies to cancer and multiple sclerosis. Putative tear fluid biomarkers of ocular disorders, as well as the more recent field of systemic disease biomarkers, will be shown.

show abstract

Section: Tear Fluid Analysis In Systemic Diseasesmentioning

confidence: 99%

Tear fluid biomarkers in ocular and systemic disease: potential use for predictive, preventive and personalised medicine

2016

View full text Add to dashboard Cite

show abstract

“…Limited data shows no correlation between elevated serum VEGF-A with ultrasound parameters of renal vasculopathy [58]. One study has reviewed VEGF-A through non-invasive sampling of tears of SSc patients and found levels to be surprisingly low possibly explained by reduced tear secretion associated with dry eye syndrome [59].…”

Section: The Potential Role Of Vegf In Ssc Related Vasculopathymentioning

confidence: 99%

The Role of Vascular Endothelial Growth Factor in Systemic Sclerosis

Flower

Barratt

Ward

et al. 2019

CRR

View full text Add to dashboard Cite

The pathological hallmarks of Systemic sclerosis (SSc) constitute an inter-related triad of autoimmunity, vasculopathy and tissue remodeling. Many signaling mediators have been implicated in SSc pathology; most focusing on individual components of this pathogenic triad and current treatment paradigms tend to approach management of such as distinct entities. The present review shall examine the role of vascular endothelial growth factor (VEGF) in SSc pathogenesis. We shall outline potential mechanisms whereby differential vascular endothelial growth factor-A (VEGF-A) isoform expression (through conventional and alternative VEGF-A splicing,) may influence the relevant burden of vasculopathy and fibrosis offering novel insight into clinical heterogeneity and disease progression in SSc. Emerging therapeutic approaches targeting VEGF signaling pathways might play an important role in the management of SSc, and differential VEGF-A splice isoform expression may provide a tool for personalized medicine approaches to disease management.

show abstract

“…VEGF is one of the components of normal tear fluid [34]. Vesaluoma et al determined VEGF concentrations in healthy tears.…”

Section: Vegf In Tear Samples Of Patients With Sscmentioning

confidence: 99%

“…Parts of this chapter are reproduced from authors' recent work mentioned in the "Reference" section and properly cited in the body of the chapter (Refs. [34,36]). Permission from authors/ publishers for the usage of the content of their articles has been obtained.…”

Section: Acknowledgementsmentioning

confidence: 99%

Ophthalmological Manifestations and Tear Investigations in Systemic Sclerosis

Rentka¹,

Köröskényi²,

Hársfalvi³

et al. 2017

Systemic Sclerosis

Self Cite

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is a chronic autoimmune disorder characterized by widespread small vessel vasculopathy, immune dysregulation with production of autoantibodies, and progressive fibrosis. There are only few reports available concerning ophthalmological complications in the course of SSc, although ocular manifestations, e.g., dry eye syndrome (DES), occurs frequently and decreases the quality of life of these patients. Vascular endothelial growth factor (VEGF), the major pro-angiogenic factor, plays a key role in the pathomechanism of SSc. Although elevated levels of VEGF in sera have already been demonstrated, VEGF analysis in tears of patients with SSc has not been performed in previous studies. VEGF in the tears of patients with SSc was found to be decreased by 20%, compared to healthy controls. The reason why the VEGF levels are not elevated in the tears of patients with SSc needs further investigations, as does the sera of the same patients. The cytokine array results revealed a shift in the cytokine profile characterized by the predominance of inflammatory mediators. Our current data depict a group of cytokines and chemokines, which play a significant role in ocular pathology of SSc; furthermore, they might function as excellent candidates for future therapeutic targets in SSc with ocular manifestations.

show abstract

Vascular Endothelial Growth Factor in Tear Samples of Patientswith Systemic Sclerosis

Cited by 22 publications

References 16 publications

Tear fluid biomarkers in ocular and systemic disease: potential use for predictive, preventive and personalised medicine

Tear fluid biomarkers in ocular and systemic disease: potential use for predictive, preventive and personalised medicine

The Role of Vascular Endothelial Growth Factor in Systemic Sclerosis

Ophthalmological Manifestations and Tear Investigations in Systemic Sclerosis

Contact Info

Product

Resources

About